Kintor Pharmaceutical Ltd (HK:9939) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kintor Pharmaceutical Ltd has successfully enrolled its first subject in the Phase III pivotal clinical trial of KX-826 tincture for treating male androgenetic alopecia in China. This trial, involving 25 clinical research centers and 666 patients, aims to assess the efficacy and safety of the 1.0% solution, expected to enhance clinical results compared to previous formulations. The study is anticipated to conclude by the end of 2025, marking a significant step for Kintor in the dermatology market.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.